Prestige Consumer Healthcare (NYSE:PBH) Upgraded by StockNews.com to Buy Rating

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Tuesday.

Several other equities analysts have also issued reports on the company. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. DA Davidson raised their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. Canaccord Genuity Group boosted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.33.

Remove Ads

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH traded down $0.24 during midday trading on Tuesday, hitting $84.12. 200,989 shares of the company's stock were exchanged, compared to its average volume of 257,341. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The business's fifty day moving average price is $82.25 and its two-hundred day moving average price is $78.53. The company has a market cap of $4.17 billion, a price-to-earnings ratio of 19.70, a PEG ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a 12-month low of $62.35 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company's stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors and hedge funds have recently modified their holdings of the company. Huntington National Bank increased its position in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after purchasing an additional 181 shares during the last quarter. Natixis Advisors LLC raised its position in Prestige Consumer Healthcare by 11.4% in the third quarter. Natixis Advisors LLC now owns 14,581 shares of the company's stock worth $1,051,000 after acquiring an additional 1,491 shares during the period. Quest Partners LLC boosted its stake in shares of Prestige Consumer Healthcare by 2,582.0% during the 3rd quarter. Quest Partners LLC now owns 11,774 shares of the company's stock worth $849,000 after acquiring an additional 11,335 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at $620,000. Finally, Eagle Asset Management Inc. increased its stake in shares of Prestige Consumer Healthcare by 0.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 434,514 shares of the company's stock worth $31,328,000 after purchasing an additional 3,227 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.